Amicus Therapeutics Inc
Company Profile
Business description
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Contact
47 Hulfish Street
PrincetonNJ08542
USAT: +1 609 662-2000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
499
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,287.90 | 84.00 | 1.02% |
| CAC 40 | 7,555.87 | 17.89 | -0.24% |
| DAX 40 | 22,449.71 | 178.04 | 0.80% |
| Dow JONES (US) | 40,491.96 | 264.37 | 0.66% |
| FTSE 100 | 8,463.46 | 46.12 | 0.55% |
| HKSE | 22,008.11 | 36.15 | 0.16% |
| NASDAQ | 17,402.95 | 36.82 | 0.21% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,025.45 | 73.44 | -0.61% |
| S&P 500 | 5,544.82 | 16.07 | 0.29% |
| S&P/ASX 200 | 8,070.60 | 73.50 | 0.92% |
| SSE Composite Index | 3,286.65 | 1.76 | -0.05% |